A curious phenomenon seen by oncologists, that morning patients do better than those receiving afternoon infusions, gains ...

Giving immunochemotherapy earlier in the day is associated with a survival benefit in NSCLC, prospective data show. But will shifting therapy delivery time be feasible in practice?

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

Administering immunochemotherapy before 3 pm vs later significantly improved survival in patients with treatment-naïve stage IIIC-IV NSCLC.

The FDA has approved Keytruda Qlex, an injected version of a popular cancer drug that until now has only been available via infusion. The FDA approved a new injected version of the cancer ...

The new consolidated facility adds four beds and better access for those being treated at the Cancer Center.

Reducing pembrolizumab infusions from 30 minutes to 10 minutes could be a safe alternative for patients and open hundreds of ...

Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...

Immunotherapy is a cancer treatment that harnesses the body’s immune system to fight cancer. It helps the immune system recognize and attack cancer cells, which can sometimes be hidden from the body’s ...

Cancer patients saved more than 60 minutes per visit when text messaging was offered as an alternative to in-person immunotherapy check-ins, according to a study published Feb. 19 in NEJM Catalyst.

Immunotherapy is a type of cancer treatment that uses the power of a person’s immune system to fight their cancer. Instead of directly attacking cancer cells like chemotherapy or radiation, ...